Clinical Trial Update: Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac) [Phase 3]

View source ↗

Summary

A Phase 3 extension study of MenBVac evaluating immune response to Neisseria meningitidis serogroup B has completed, involving 16 vaccinated participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenBVac (Meningococcal B vaccine)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Vaccination With MenbVac | Phase 3 | Status: COMPLETED